Aparna Parikh, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    C2i genomics
    Topic:
    Advisor/consultant
    Date added:
    11/16/2021
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Pfizer
    Topic:
    Advisor/consultant
    Date added:
    11/16/2021
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Roche
    Topic:
    Advisor/consultant
    Date added:
    11/16/2021
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Eli Lilly
    Topic:
    Advisor/consultant
    Date added:
    11/16/2021
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Inivata
    Topic:
    Advisor/consultant
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Biofidelity
    Topic:
    Advisor/consultant
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Natera
    Topic:
    Advisor/consultant
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Checkmate Pharmaceuticals
    Topic:
    Advisor/consultant
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    FMI
    Topic:
    Advisor/consultant
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Guardant
    Topic:
    Advisor/consultant
    Date added:
    04/14/2022
    Date updated:
    04/17/2023

Pages

Return to 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology